Skip to main content
Premium Trial:

Request an Annual Quote

Benitec Selects Duke as Site for HCV Drug Trial

Premium

Benitec Biopharma announced last week that it has selected the Duke Clinical Research Unit as a site for its upcoming phase I/II trial for the expressed RNAi-based hepatitis C infection treatment TT-034.

The trial is designed to evaluate single escalating doses of the drug in patients with chronic HCV genotype I infection who have failed previous treatment, Benitec said.

It is expected to enroll 14 patients in five sequential dose cohorts, with the possibility of additional cohorts added to confirm study findings. Endpoints include safety, as well as serum viral load reduction and hepatocyte transduction levels.

Patient enrollment is expected to begin in the second half of the year.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.